Paul Tudor Jones Apellis Pharmaceuticals, Inc. Transaction History

Tudor Investment Corp Et Al

$26.8 Billion
Q3 2024

A detailed history of Paul Tudor Jones (Tudor Investment Corp Et Al) transactions in Apellis Pharmaceuticals, Inc. stock. As of the latest transaction made, Tudor Investment Corp Et Al holds 73,002 shares of APLS stock, worth $2.42 Million. This represents 0.01% of its overall portfolio holdings.

Number of Shares

73,002

Holding current value

$2.42 Million

% of portfolio

0.01%

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 14, 2024	BUY	$28.84 - $41.15 $2.11 Million - $3 Million	73,002 New	73,002 $2.11 Million
Q4 2023 Feb 14, 2024	SELL	$37.14 - $64.82 $1.49 Million - $2.6 Million	-40,150 Reduced 80.12%	9,962 $596,000
Q3 2023 Nov 15, 2023	BUY	$23.65 - $89.22 $1.01 Million - $3.81 Million	42,714 Added 577.37%	50,112 $1.91 Million
Q2 2023 Aug 14, 2023	BUY	$76.68 - $93.31 $567,278 - $690,307	7,398 New	7,398 $673,000
Q2 2022 Aug 15, 2022	SELL	$35.07 - $59.21 $495,644 - $836,814	-14,133 Reduced 28.94%	34,707 $1.57 Million
Q1 2022 May 16, 2022	BUY	$35.46 - $54.12 $1.73 Million - $2.64 Million	48,840 New	48,840 $2.48 Million
Q4 2021 Feb 14, 2022	SELL	$30.74 - $49.16 $4.63 Million - $7.41 Million	-150,703 Closed	0 $0
Q3 2021 Nov 15, 2021	BUY	$31.4 - $69.84 $4.02 Million - $8.94 Million	128,065 Added 565.71%	150,703 $4.97 Million
Q2 2021 Aug 16, 2021	BUY	$40.9 - $64.9 $925,894 - $1.47 Million	22,638 New	22,638 $1.43 Million
Q1 2021 May 17, 2021	SELL	$40.8 - $57.39 $1.2 Million - $1.69 Million	-29,448 Closed	0 $0
Q4 2020 Feb 16, 2021	BUY	$30.79 - $57.2 $292,720 - $543,800	9,507 Added 47.68%	29,448 $1.68 Million
Q3 2020 Nov 16, 2020	BUY	$25.89 - $33.65 $516,272 - $671,014	19,941 New	19,941 $602,000

Others Institutions Holding APLS

# of Institutions

308

Shares Held

115M

Call Options Held

3.85M

Put Options Held

1.09M

View Full List

About Apellis Pharmaceuticals, Inc.

Ticker APLS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 109,865,000
Market Cap $3.64B
Description
Apellis Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. The company's lead product candidate is pegcetacoplan that is in Phase III clinical trials for...

More about APLS

Track Paul Tudor Jones's Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Tudor Investment Corp Et Al, based on Form 13F filings with the SEC.

News

Stay updated on Tudor Investment Corp Et Al and Paul Tudor Jones with notifications on news.

Account